Literature DB >> 7654477

A suggested approach to once-daily aminoglycoside dosing.

E J Begg1, M L Barclay, S B Duffull.   

Abstract

1. Once-daily aminoglycoside dosing has many advantages and has been widely advocated. However, existing guidelines for methods of administration and monitoring are non-specific and may lead to excessive dosing. 2. The traditional approach of aiming for target peak and trough concentrations is not appropriate for once-daily dosing. 3. A method is proposed which uses a target area under the concentration-time curve (AUC) for the aminoglycoside based on the 24 h AUC that would result with conventional dosing. This method requires measurement of two drug concentrations, one approximately 0.5 h after the end of the infusion and another at a later time (6-22 h) depending on renal function. 4. A simpler, graphical method is also proposed for patients with normal renal function, which requires the measurement of a single concentration at a time between 6 and 14 h. 5. Both methods are likely to be safer than existing guidelines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654477      PMCID: PMC1365071     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Once-daily aminoglycosides.

Authors:  D Nicolau; R Quintiliani; C H Nightingale
Journal:  Conn Med       Date:  1992-10

Review 2.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Once-daily aminoglycoside dosing.

Authors:  S E Parker; P G Davey
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

4.  Once-daily aminoglycoside dosing.

Authors:  G E Bignardi; U Riley
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

Review 5.  Practicalities of once-daily aminoglycoside dosing.

Authors:  S E Parker; P G Davey
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

6.  Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.

Authors:  F Konrad; R Wagner; B Neumeister; H Rommel; M Georgieff
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

7.  Kinetic model for gentamicin dosing with the use of individual patient parameters.

Authors:  R J Sawchuk; D E Zaske; R J Cipolle; W A Wargin; R G Strate
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

8.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

9.  Prediction equation estimates of creatinine clearance in the intensive care unit.

Authors:  G R Pesola; I Akhavan; A Madu; N K Shah; G C Carlon
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 10.  What is the evidence for once-daily aminoglycoside therapy?

Authors:  M L Barclay; E J Begg; K G Hickling
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

View more
  51 in total

1.  Aminoglycoside dosage regimens after therapeutic drug monitoring.

Authors:  Carl M J Kirkpatrick; Evan J Begg; Murray L Barclay; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury.

Authors:  Jason A Roberts; Jonathan Field; Adam Visser; Rosemary Whitbread; Mandy Tallot; Jeffrey Lipman; Carl M J Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

4.  Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs.

Authors:  Mitali Mohan; Kevin T Batty; Jennifer A Cooper; Richard E Wojnar-Horton; Kenneth F Ilett
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

5.  Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.

Authors:  Stefanie Hennig; Ross Norris; Carl M J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

6.  Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.

Authors:  Michael A Barras; David Serisier; Stefanie Hennig; Katrina Jess; Ross L G Norris
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

7.  Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation.

Authors:  Kristi L Higgins; Cady Noda; Jeremy S Stultz
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

8.  The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration.

Authors:  Claire Johnston; Sarah N Hilmer; Andrew J McLachlan; Slade T Matthews; Peter R Carroll; Carl M Kirkpatrick
Journal:  Eur J Clin Pharmacol       Date:  2014-02-14       Impact factor: 2.953

9.  Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered.

Authors:  Anne Veinstein; Nicolas Venisse; Julie Badin; Michel Pinsard; René Robert; Antoine Dupuis
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

10.  Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

Authors:  Yanhua Gao; Stefanie Hennig; Michael Barras
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.